Investors Buy Large Volume of Call Options on Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences Corporation (NYSE:EW) saw unusually large options trading on Monday. Stock traders purchased 2,518 call options on the stock. This is an increase of 93% compared to the average volume of 1,303 call options.

Insider Transactions at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 544 shares of the company’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares of the company’s stock, valued at $1,353,880.08. This represents a 3.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $87.51, for a total transaction of $54,168.69. Following the sale, the vice president owned 40,034 shares in the company, valued at $3,503,375.34. The trade was a 1.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 5,664 shares of company stock valued at $511,918. 0.31% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Edwards Lifesciences

A number of hedge funds have recently modified their holdings of the business. Rehmann Capital Advisory Group raised its position in Edwards Lifesciences by 2.1% in the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock valued at $546,000 after purchasing an additional 130 shares in the last quarter. Stephens Inc. AR grew its position in shares of Edwards Lifesciences by 5.4% during the fourth quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company’s stock worth $239,000 after buying an additional 144 shares in the last quarter. Aspen Investment Management Inc grew its position in shares of Edwards Lifesciences by 1.5% during the fourth quarter. Aspen Investment Management Inc now owns 10,381 shares of the medical research company’s stock worth $885,000 after buying an additional 150 shares in the last quarter. NorthRock Partners LLC increased its stake in shares of Edwards Lifesciences by 1.0% during the second quarter. NorthRock Partners LLC now owns 16,191 shares of the medical research company’s stock worth $1,465,000 after buying an additional 153 shares during the period. Finally, Covestor Ltd increased its stake in shares of Edwards Lifesciences by 9.6% during the fourth quarter. Covestor Ltd now owns 1,784 shares of the medical research company’s stock worth $152,000 after buying an additional 157 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on EW shares. Piper Sandler reaffirmed an “overweight” rating and set a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Citigroup boosted their price objective on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their target price for the company from $87.00 to $101.00 in a report on Friday, July 24th. Truist Financial lifted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. Finally, TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $100.27.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $85.71 on Wednesday. The stock’s 50-day moving average is $88.79 and its 200-day moving average is $85.85. Edwards Lifesciences has a 1-year low of $72.30 and a 1-year high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The stock has a market cap of $49.35 billion, a P/E ratio of 49.26, a price-to-earnings-growth ratio of 2.24 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same quarter last year, the business earned $0.67 EPS. The firm’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts anticipate that Edwards Lifesciences will post 3 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.